In the wake of fears of a third wave of corona in the country, Kovaxin manufacturing company Bharat Biotech is going to start a clinical trial on children from June. The company hopes to get a vaccine license for children by the third quarter of the year. The company's Business Development and International Advocacy Head, Dr. Rachets Ailla, said that the company could start pediatric trials of its vaccine from June. Bharat Biotech recently received approval from the Drug Controller General of India for clinical trials for children aged 2-18 years.
70 crore vaccine production by the end of the year
Through video conferencing at an event of FICCI's Women's Wing in Hyderabad, Dr. Raches Ella said that the company would get approval from the World Health Organization (WHO) for covaxine by the end of the third or fourth quarter. Responding to a question in the program, Dr. Raches Ella said that he is happy that the company's hard work is paying off and the vaccine is working well and saving people's lives. The company says that it will increase its production capacity to 70 million by the end of this year.
Rs 1500 crore advance given
Dr. Raches Ella said that the vaccine is being prepared in collaboration with Biotech and ICMR. So far, full support and support are being received from the government. Has been done. The government has placed an advance order of Rs 1,500 crore vaccine. Subsequently, the company is also expanding in Bangalore and Gujarat. The company will increase its vaccine manufacturing capacity to 70 million doses by the end of this year.
Fear of the third wave
Significantly, in the third wave of Corona, children are expected to be the most affected. Many health experts believe that the third wave of Corona in September will wreak havoc, affecting mostly children. Explain that there are three vaccines available in India. Kovishield, Kovaxin and Russia's Sputnik V. However, some pharma companies have demanded the government to allow the center to manufacture vaccines.